Recent studies have reported that MORC2 is upregulated in most cancers including the lung, kidney, breast, liver, etc. [9,10], and the high expression of MORC2 in cancer cells is not only related to tumorigenesis and metastasis [8,11], but also associated with drug resistance in tumor therapy, including radiation, chemotherapy, and endocrine resistance [11,12,13,14]. Here, MORC2 is linked to neoplasm.